AYTU BIOPHARMA, INC

AYTU BIOPHARMA, INC

AYTU Biopharma (formerly known as Aytu BioScience) was founded in 2015 as a specialty pharmaceutical company. The company's strategy centers on acquiring, developing, and commercializing late-stage or approved therapeutics, primarily in the women's health and urology segments. AYTU's lead asset, AYF 31 (a reformulation of fluconazole), targets a large addressable market for vaginal yeast infections, with clinical data suggesting potential for an over-the-counter switch. The firm also commercializes a portfolio of prescription and OTC products through its Aytu BioRx segment, which distributes compounded and branded medications. The company is headquartered in Englewood, Colorado, with additional operations in the United States. AYTU operates a hybrid model: it employs a small internal commercial team while outsourcing manufacturing to third-party contract manufacturers and conducting clinical trials through CROs. As of its most recent filings, AYTU reported total assets of $12.3 million and annual revenue of $8.5 million (per SEC filings, fiscal year 2024). The company is publicly traded on the Nasdaq under the ticker AYTU. AYTU's structural differentiator is its focus on drug repurposing and reformulation rather than novel drug discovery, reducing clinical risk. The company also maintains a high degree of operational leverage by relying on outsourced production and a virtual R&D model. However, the firm faces significant financial headwinds, including negative cash flow from operations and a diluted equity base.